AI summary by TwinMind
23andMe ft. Anne Wojcicki - How a DNA startup took on the FDA and redefined health tech
Sequoia Capital
38m 15s
Company Foundation and Early Vision (2006)
- Anne Wojcicki co-founded 23andMe in 2006 to revolutionize healthcare industry
- First company to offer direct affordable access to genome information
- Mission: help people access, understand, and benefit from human genome
- Background: Wojcicki spent 10 years investing in healthcare companies
- Realized healthcare system optimized to monetize patients rather than serve them
- Patients lacked voice in their own healthcare decisions
- Timing advantage: human genome 92% sequenced, costs declining rapidly
- Vision: create community focused on people's interests vs. corporate bottom lines
Groundbreaking Product Launch and Market Discovery
- Initial launch features:
- Democratized genome access (previously cost $1M+ for individuals)
- Provided information medical community wouldn't return (e.g., Alzheimer's risk)
- Parkinson's testing driven by Sergey Brin's personal interest
- Created consented database for relative finder and ancestry composition
- Launch success: New York Times cover story, Wired cover, Fashion Week party
- Pricing evolution:
- Started at $1,000 price point
- Sold 1,000 kits first day, then dropped to 15-20 kits/day
- Cut price to $99, sold 17,000-18,000 kits in one day
- Exhausted entire inventory in single day
- Raised Series C funding based on demand data
Medical Establishment Resistance
- Heavy discrediting from medical profession in early days
- Medical meetings refused 23andMe attendance due to direct-to-consumer model
- Physician walked out of dinner, predicted "destruction in people's lives" due to non-paternity rates
- Fear about genetics information and consumer behavior without physician supervision
- Concerns unsubstantiated by data
FDA Regulatory Crisis (November 2013)
- FDA ordered 23andMe to shut down all health testing services
- Warning letter became public days later
- David Kessler (former FDA commissioner) warned Wojcicki about letter's seriousness
- Three response options considered:
- Fold company (rejected immediately)
- Fight FDA (customer support existed)
- Full compliance (chosen path)
- Regulatory leader advised: "Put your head down and do the work... slow and painful... years"
Regulatory Compliance Journey (2014-2015)
- Hired Cathy Hibbs as Chief Legal and Regulatory Officer (April 2014)
- Major transition from unregulated to regulated company
- FDA requirements:
- Prove report accuracy through technical challenges
- Demonstrate consumer comprehension through testing
- Two years of meticulous testing and data provision
- FDA authorization received in 2015
- Standing ovation for regulatory team achievement
- Competitive advantage: only company with FDA-approved tests
Business Growth During Regulatory Period
- Ancestry product sales accelerated 2014-2015
- Reached scale of 100,000+ people, approaching 1 million
- Became largest consented genetic database in world
- Database size enabled interesting research opportunities
Therapeutics Division Launch (2015)
- Wojcicki's original vision: use human genetic data for drug discovery
- Drugs with genomic foundation 2-3x more likely to succeed
- Hired Richard Scheller (retired Genentech executive) as head of Therapeutics
- Built laboratory from scratch:
- No existing lab facilities (closest was kitchen)
- Bought used equipment from company auctions
- Hired talented team, moved to laboratory space
- Focused on antibody therapeutics as more straightforward approach
- Identified multiple drug targets worth pursuing
- GSK collaboration: 50+ programs identified
- Database grew to 12-14 million people (largest in world)
Peak Brand Awareness and Market Saturation (2018-2019)
- 2018: Incredible inflection point, kit sales took off
- Brand awareness hit all-time high:
- Lizzo dressed as 23andMe for Halloween
- Eddie Murphy discussed 23andMe on Saturday Night Live
- Featured in crossword puzzles and jokes
- 2019: Sales started to flatline
- Contributing factors:
- Privacy concerns (Cambridge Analytica, Golden State Killer)
- Increased competition from Ancestry.com
- Company focused on health while ancestry market grew
- Insufficient marketing investment during growth period
Business Pivot and Workforce Reduction (2019)
- Laid off 100 people (14% of workforce)
- Readjusted marketing budgets and spend
- Emphasized choice and transparency principles
- Pivoted from information provider to full-stack healthcare solution
- Subscription model with ongoing updates on genetic information
Telehealth Expansion (2020-2021)
- Initially skeptical about telemedicine feasibility (2019 offsite)
- COVID-19 pandemic accelerated telemedicine acceptance
- Acquired Lemonade Health (closed November 2021):
- Clinicians licensed in all 50 states
- Online pharmacy capabilities
- Pharmacogenomics opportunities (medication optimization based on genome)
- Still harmonizing acquisition and bringing services together
Current Drug Development Success
- June 1, 2023: Announced 23ME-610 investigational cancer drug
- First-of-its-kind antibody for advanced cancers
- Moving into Phase 2 testing:
- Phase 1: Demonstrated safety and tolerability
- Phase 2: Testing efficacy in patients
- Long development road ahead but significant milestone
Medical Community Transformation
- Survey results: 90%+ of physicians understand genetics' clinical value
- Massive transformation in medical acceptance
- Team endured continuous proof of information accuracy and safety
- Slowly won over medical world through persistent data-driven approach
Future Vision and Leadership Philosophy
- Goal: World's only leader in genomic-based medicine
- Personalized prevention focus:
- Customized screening schedules (colonoscopy, mammograms)
- Genetic-specific recommendations (e.g., fava bean toxicity)
- Keeping people healthy vs. treating illness
- Crucible moments as innovation opportunities
- Brand risk-taking philosophy: "Why else have a brand if you don't want to take risks?"
- Leadership focus on inspiration and vision maintenance
